Your session is about to expire
← Back to Search
Vitamin Supplement
4000 IU Vitamin D for Osler-Weber-Rendu Syndrome
Phase 2
Waitlist Available
Research Sponsored by St. Paul's Hospital, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months, and 6 months
Awards & highlights
Summary
This trial is testing if taking vitamin D regularly can help reduce the frequency and severity of nosebleeds in patients with HHT. Vitamin D might make blood vessels stronger and less likely to bleed. The study will compare different amounts of vitamin D to see which works best.
Eligible Conditions
- Osler-Weber-Rendu Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 3 months, and 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months, and 6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Epistaxis Severity Score
Secondary outcome measures
Change in Modified Lund-Kennedy Score
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: 4000 IU Vitamin DExperimental Treatment1 Intervention
Group II: 1000 IU Vitamin DExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vit D
2016
Completed Phase 4
~1210
Find a Location
Who is running the clinical trial?
St. Paul's Hospital, CanadaLead Sponsor
44 Previous Clinical Trials
12,660 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger